TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone and Two Doses of Misoprostol for Abortion at 11&12 Weeks

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Seeking medical abortion services at one of the enrolling clinics~* Have an intrauterine pregnancy 71-77 days of gestation or 78-84 days~* Meet standard eligibility criteria for medical abortion~* Be able to return to clinic for in-person follow up~* Speak/read/write English or Spanish~* Have access to a mobile phone with texting capability~* Be in general good health~* Be willing and able to sign consent forms~* Agree to comply with the study procedures and follow up.~Exclusion Criteria:~* Not eligible to consent on their own to being in a study (Age criteria may vary by site according to state law.)~* With known allergies or other contraindications to mifepristone or misoprostol~* Desiring to start depot medroxyprogesterone acetate (DMPA) as contraception method immediately because of potential interaction with mifepristone. Those who wish to wait until abortion completion to start DMPA will be eligible for enrollment.

- Gender: FEMALE
- Minimum Age: 11 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 71-77 days of gestational age (Type: NO_INTERVENTION): Pregnant people whose pregnancies are estimated to have a gestational age of 71-77 days. (Participants in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range).
- 78-84 days of gestational age (Type: EXPERIMENTAL): Pregnant people whose pregnancies are estimated to have a gestational age of 78-84 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Ages 10-21 years~2. Known diagnosis of CF based on sweat chloride \> 60 mEq/L or identification of two known Cystic fibrosis transmembrane conductance regulator (CFTR) mutations~3. Clinically stable pulmonary disease defined by~   1. clinical impression of patient's primary CF provider,~  2. no newly prescribed antibiotic treatments in the 30 days prior to enrollment, and~  3. relativly stable lung function with a forced expiratory volume in 1 second (FEV1) within 10% of baseline.~4. Male and female~5. Willing to participate in and comply with all study procedures, and~6. Willingness of the subject, parent or legally authorized representative to provide written informed consent.~7. Body Mass Index (BMI) \>25%~8. \>40% FEV1.~9. Willing to stop acid blockade medication for 6 weeks for aim 1.~10. Not on acid blockade for 6 weeks for aim 2.~Exclusion Criteria:~1. FEV1 less than 40% predicted~2. History of meconium ileus, distal intestinal obstructive syndrome, gastrointestinal surgery, or intestinal stricture.~3. CF liver disease with cirrhosis, gastric or esophageal varices.~4. Unwilling to participate in and comply with the study procedures.~5. Unwillingness of the subject, parent or legally authorized representative to provide written informed consent.~6. Unwilling or unable to swallow the capsule with the esophageal string test (EST).~7. Gelatin allergy.~8. History of esophageal surgery including fundoplication, or~9. Presence of a gastrostomy tube.~10. Confirmed or suspected diagnosis of Gastroesophageal Reflux Disease (GERD)~11. BMI \< 25%

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- ON PPI (Type: None): Subjects on proton pump inhibitor (PPI) treatment
- OFF PPI (Type: None): Subjects off proton pump inhibitor (PPI) treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Asymptomatic Bacteriuria in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women ≥ 18 years of age seeking prenatal care at the Academic Obstetrics and Gynecology Center at St. Joseph Mercy Hospital, Ann Arbor, Michigan~* Randomization will occur if the patient every has a urine culture demonstrating ≥10,000 cfu/ml of a pathogenic urinary tract organism~Exclusion Criteria:~* Symptomatic bacteriuria (cystitis or pyelonephritis) at the time of urine collection~* Previously treated bacteriuria in current pregnancy~* Past medical history of known congenital or acquired urinary tract anomaly or abnormality (i.e. pelvic kidney, single kidney, renal transplant)~* Any antibiotic use within the week prior to urine sampling~* Urine culture revealing growth of the following organisms: Lactobacillus, coagulase-negative staphylococcus

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 3-day treatment (Type: EXPERIMENTAL): Three-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.
- 7-day treatment (Type: ACTIVE_COMPARATOR): Seven-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Breast cancer requiring neoadjuvant or adjuvant therapy with doxorubicin~* Complete metabolic panel demonstrating adequate organ functions as defined by the following: Aspartate transaminase (AST) less than 2.5 times Upper Limit of Normal (ULN); Alanine transaminase (ALT) less than 2.5 times ULN; alkaline phosphatase less than 2.5 times ULN; serum creatinine less than 1.5 mg/dL; serum bilirubin less than ULN~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Age greater than or equal to 21 years~Exclusion Criteria:~* Known diabetes~* History of cardiac arrhythmias or symptomatic cardiac disease~* Currently taking antiarrhythmic medications, beta-blockers, or other rate controlling cardiac medications~* Currently taking metformin and/or sulfonylureas~* Known hypersensitivity or intolerance to metformin~* Baseline ejection fraction of less than 50% measured by echocardiogram~* Known hypersensitivity to contrast used during echocardiogram~* Risk factors associated with increased risk of metformin-associated lactic acidosis (e.g. congestive heard failure, history of acidosis, habitual intake of 3 or more alcoholic beverages per day)~* Pregnant or breast feeding

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: ACTIVE_COMPARATOR): Patients will receive standard of care for their breast cancer with no metformin during their treatment with doxorubicin.
- Metformin + Standard of Care (Type: EXPERIMENTAL): Patients will receive metformin during their treatment with doxorubicin for their breast cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* COVID-19 infection diagnosed by nasopharyngeal sample~* Need for supplemental oxygen to maintain oxygen saturation \> 93%~* 12 years of age or older~Exclusion Criteria:~* Neutrophils \< 1 x 10\^9/L~* Platelets \< 50 x 10\^9/L~* Serum total bilirubin \>2.0 x upper limit of normal (ULN)~* Aspartate aminotransferase (AST), or alanine aminotransferase (ALT) \> 5x ULN~* Creatinine clearance (CrCl) \< 15 mL/minute~* Pregnant women~* Known HBV or HIV infection~* Signs and symptoms of Varicella Zoster Virus (VZV) infection~* Patients requiring invasive mechanical ventilation. Patients requiring non-invasive mechanical ventilation (e.g., BiPAP) are eligible.~* Patients who require supplemental oxygen support prior to COVID-19 infection.~* Patients who are on ruxolitinib or similiar drugs.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib to prevent COVID-19 pneumonia (Type: EXPERIMENTAL): All participants will receive ruxolitinib at at 10 mg, twice a day, for 14 days, followed by 5 mg, twice a day, for 2 days and 5 mg, once daily, for 1 day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dynamic Substrate Mapping (DSM) for Ischemic VT

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have an ICD or CRT-D device~* Had at least 3 documented device therapies to treat VT over last 3 months~* Clinical VT is confirmed or suspected to be of ischemic origin~* Scheduled for VT ablation procedure~* LVEF \> or = 20%~Exclusion Criteria:~* Inadequate AAD washout (amiodarone should be maintained at current dose)~* Unstable angina~* Active ischemia~* Cardiac surgery within prior 2 months~* Evidence of infection~* Prosthetic mitral or aortic valve or mitral/aortic valvular heart disease requiring surgical intervention~* History of embolic event~* Myocardial infarction within prior 6 weeks~* Enrolled in another study~* Recurrent sepsis or otherwise not a candidate for catheterization~* Hypercoagulable state or inability to tolerate heparin therapy during procedure~* Has had an atriotomy or ventriculotomy within prior 4 months~* Life expectancy \< 6 months~* Class IV NYHA classification

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DSM (Type: ACTIVE_COMPARATOR): Treatment using DSM to guide ablation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Olfactory and Visual Perception in Depressed Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* no cognitive impairment that could prevent instruction comprehension~* no more than 10 cigarettes/day~* signed informed consent~* group 1: current major depressive disorder~* group 2: no current major depressive disorder~Exclusion Criteria:~* pregnancy~* visual impairment~* olfactory impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- depressed patients (Type: EXPERIMENTAL): patient with a current unipolar major depressive disorder intervention: olfactory assessment, image visualization and psychophysiological assessment
- non depressed subject (Type: EXPERIMENTAL): subject without a current unipolar major depressive disorder intervention: olfactory assessment, image visualization and psychophysiological assessment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Point-of-Care Ultrasound Educational Initiative for Insect Bites

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Erythema or swelling surrounding an insect bite or sting for greater than 12 hours~Exclusion Criteria:~* Patients with skin findings consistent with an abscess (ie. active drainage, fluctuance)~* Patients who are relatively immunocompromised (e.g., patients with AIDS, diabetes mellitus, cancer)~* Recent use of antibiotics within 1 week prior to symptoms~* Pregnant~* Altered mental status~* Unable to provide a phone number for follow-up

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Pre-Intervention (Type: NO_INTERVENTION): Current practice (unchanged). This arm of patients will cared for by physicians who have NOT received the POCUS Educational Intervention.
- Post-Intervention (Type: EXPERIMENTAL): This arm of patients will cared for by physicians who have received the POCUS Educational Intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects Of Yoga On Quality Of Life Among A Population Of Ovarian/ Fallopian Tube/ Primary Peritoneal Cancer Patients Receiving Chemotherapy: A Feasibility Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of epithelial ovarian/fallopian tube/primary peritoneal cancer~* Participant must be age 18 or older~* Participants must be 6 weeks post-surgery~* Participant must be currently receiving chemotherapy or beginning a regimen within the next four weeks~* Participant must be willing to attend the intervention sessions~* All subjects must have given signed, informed consent prior to registration in the study.~Exclusion Criteria:~* Participant has practiced yoga more than 4 times in the last year~* Participant has a surgical procedure scheduled during the 8 weeks that they would be part of the intervention~* Participant has an ECOG performance status less than or equal to two

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No Intervention; Arm A; Control Group (Type: NO_INTERVENTION): 24 subjects who declined yoga but agreed to data collection
- Active Comparator; Arm B; Intervention Group (Type: ACTIVE_COMPARATOR): 24 subjects participating in 8 weeks of Yoga and agreed to data collection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
* Inclusion Criteria:~  1. Age 18 to 80 yrs at randomization~ 2. History of Type 2 Diabetes~ 3. Presence of systolic hypertension or pre-hypertension (average systolic blood pressure (SBP) ≥120 mmHg and \<180 mmHg.)~ 4. Urinary protein/creatinine ratio \>300 mg/g creatinine at screening~ 5. Hemoglobin A1C\<8%~ 6. Willing and able to give informed consent~* Exclusion Criteria:~  1. Average SBP of ≥180 mmHg or diastolic blood pressure (DBP) of ≥110 mmHg~ 2. Current symptomatic heart failure, history of New York Heart Association Class III or IV congestive heart failure, or left ventricular (LV) ejection fraction (by any method) \<25%; these patients may be harmed with withdrawal of diuretics~ 3. Serum potassium level \<3.5 or \>5.0 at screening~ 4. History of hyperkalemia in the last two years (serum K\>5.5)~ 5. Contraindication to use of hydrochlorothiazide or amiloride~ 6. Unstable angina pectoris or acute myocardial infarction (MI) in last 3 months~ 7. Known secondary causes of hypertension (HTN) (screening for these conditions will not be required)~ 8. Estimated glomerular filtration rate (GFR) \<60 mL/min/1.73m², as determined by validated estimating equations~ 9. On or expected to be on immunosuppressive therapy~ 10. Any history of solid organ transplantation~ 11. Significant dementia~ 12. Other factors likely to limit adherence during trial (eg. alcohol or substance abuse, plan to move in next year, history of non-adherence to medications, appointments and medical care, reluctance of close family members to participate in trial, lack of support from primary healthcare provider)~ 13. Participation in another investigational trial within 4 weeks of the screening visit~ 14. Arm Circumference too large or too small to allow accurate blood pressure measurement~ 15. Pregnancy or currently trying to become pregnant (although this is unlikely because of age limit~ 16. Incarceration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Amiloride 10 mg, 20 mg, and diet (Type: EXPERIMENTAL): Amiloride 10 mg for 14 days and diet. Then dose titrated up at day 14 to 20 mg, and diet.
- HCTZ 12.5 mg, 25 mg and diet (Type: ACTIVE_COMPARATOR): HCTZ 12.5 mg for 14 days and diet. Then dose titrated up at day 14 to 25 mg, and diet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: High Resolution Manometry for Swallowing

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80~* Healthy Volunteer~* No clinical evidence of dysphagia~Exclusion Criteria:~* History of prior dysphagia~* Prior esophageal or gastric dysmotility secondary to systemic conditions (scleroderma or diabetes mellitus)~* Known gastrointestinal malignancy~* Use of medications known to affect esophageal or gastric motility (e.g. anticholinergics, opiates, calcium channel blockers)~* Previous esophageal or gastric surgery~* Significant cardiac or respiratory disease~* Pregnancy (a pregnancy test will be performed in women of child-bearing potential)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- esophageal manometry (Type: EXPERIMENTAL): Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Myocardial Infarction - Stress Prevention Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years~* STEMI (ST-elevated myocardial infarction) or non-STEMI~* Stable circulatory condition~* Numeric Rating Scale (NRS) (0-10): a score of at least 5 for pain (during MI) plus a score of at least 5 for fear of dying (until admission to the CCU) and/or making sorrows and feeling helpless (when being told about having MI)~* Written informed consent~Exclusion Criteria~* Participating in any other randomized-controlled trial run by the Cardiology Department of the University Hospital of Bern~* Emergency coronary artery bypass graft surgery~* Comorbid serious disease likely to cause death within 1 year~* Current clinically severe depression~* Not fully oriented to the situation, person, and place~* Cognitive impairment according to an adapted short version of the Mini-Mental State Examination~* Insufficient knowledge of German language in reading and understanding~* Affirmation of suicidal ideation in the last two weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Patients in the intervention group will participate in one single counseling session of 45 minutes (the minimal behavioral intervention) that targets specific MI-triggered traumatic reactions.
- Control group (Type: ACTIVE_COMPARATOR): Patients in the control group will participate in one single counseling session of 45 minutes (the control intervention) that targets more general information about the role of psychological stress in coronary heart disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Transcranial Direct Current Stimulation on Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Peripheral Neuropathy~* Walking independently but with problems with balance~Exclusion Criteria:~* Prominent weakness at the ankle~* Not able to walk independently~* History of Seizure~* Cardiac Pacemaker~* Metal implants in the head~* Increased intracranial pressure~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- dTCS (Type: EXPERIMENTAL): Patient will receive dTCS with direct current (maximum of 2 mA) stimulation delivered through surface electrodes (TransQE from IOMED®, surface area: 25 cm2) using a Phoresor® II Auto (Model No. PM850, IOMED®, Salt Lake City, Utah 84120, USA) or Sham stimulation.
- Sham (Type: SHAM_COMPARATOR): Patients will receive a sham.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility